

Cynata Appoints New Chief Business Officer

Melbourne, Australia; 29 February 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has appointed experienced biopharmaceutical executive Dr Mathias Kroll to the newly created position of Chief Business Officer, commencing in mid-April.

Dr Kroll joins Cynata from QIMR Berghofer Medical Research Institute, where he has been Chief Commercial Officer since 2019. During his career of over twenty-five years, he has held leadership positions in companies of varying sizes, including three of the world’s largest multinationals (Bayer, Sanofi-Aventis and GlaxoSmithKline). He has also led a European biotechnology company as CEO. Between his academic and industry roles, he has been based in nine countries on four continents, showcasing his versatility and in-depth knowledge of the sector at a global level.

In his early career, Dr Kroll worked at a top tier global consultancy group, then moved into the pharmaceutical industry as research group leader, and subsequently marketing manager in charge of a large product franchise. For the past two decades, he has focussed on corporate and business development. He has a strong track record in establishing and extracting value from partnerships between companies, investors, and other stakeholders, to fund the development and commercialisation of biopharmaceutical products. He has successfully concluded numerous international deals, across all stages of the pharmaceutical value chain, some of which have exceeded a billion dollars in value. Many of his deals were driven by matching specialised manufacturing capacity and capability with innovative therapies.

Dr Kroll obtained Master of Science (MSc) equivalent honours degrees in chemistry and biology, following university studies in Germany, the United States, and France. He was later awarded a PhD in immunology for his thesis at the Pasteur Institute in France, and an MBA from the International Institute for Management Development (IMD) in Switzerland. He has also completed training in patent law and is a graduate of the Australian Institute of Company Directors.

Dr Kroll said:

“I am thrilled to join Cynata as Chief Business Officer, with responsibility for business development, finance, and investor relations. Cynata offers a groundbreaking solution to the challenge of producing high-quality regenerative cell therapy products at scale and in a consistent way. With its unique technology, Cynata is well positioned to catalyse the transformation of regenerative cell therapies from relatively isolated, individual applications into universally accessible therapies which can be manufactured at scale to reach patients worldwide. In addition, the current advances in Cynata’s own product development pipeline boost the Company’s potential to originate novel therapies in areas of high need. My objective is to establish the partnerships that will realise the full potential of both Cynata’s core technology and candidate products.”

Dr Kilian Kelly, Cynata’s Chief Executive Officer, said:

“We have created this new position in anticipation of the next stage of the Company’s growth, with a particular focus on business development and partnering. I am very much looking forward to working with Mathias as a key member of our executive leadership team, to advance the commercialisation of our Cymerus™ off-the-shelf iPSC¹-derived MSC² products. Mathias has a tremendous amount of highly relevant and genuinely global experience, and I am confident that he has the expertise and attributes to help us achieve our goals in the years ahead.”

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (0)3 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

¹ iPSC = induced pluripotent stem cell

² MSC = mesenchymal stem (or stromal) cell



About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.